Preclinical evaluation of antitumor activity of the proteasome inhibitor MLN2238 (ixazomib) in hepatocellular carcinoma cells

Hepatocellular carcinoma (HCC) is one of the common malignancies and is an increasingly important cause of cancer death worldwide. Surgery, chemotherapy, and radiation therapy extend the 5-year survival limit in HCC patients by only 6%. Therefore, there is a need to develop new therapeutic approache...

Descripción completa

Detalles Bibliográficos
Autores principales: Augello, Giuseppa, Modica, Martina, Azzolina, Antonina, Puleio, Roberto, Cassata, Giovanni, Emma, Maria Rita, Di Sano, Caterina, Cusimano, Antonella, Montalto, Giuseppe, Cervello, Melchiorre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5833482/
https://www.ncbi.nlm.nih.gov/pubmed/29348495
http://dx.doi.org/10.1038/s41419-017-0195-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5833482/
https://www.ncbi.nlm.nih.gov/pubmed/29348495
http://dx.doi.org/10.1038/s41419-017-0195-0

Ejemplares similares